Keywords: promising, new, data, abbott, abt-510, angiogenesis, inhibitor
Promising new data for Abbott's ABT-510
Article | 16 June 2003
ABT-510, an angiogenesis inhibitor under development with Abbott Laboratories, demonstrated a good safety profile and preliminary efficacy in a Phase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
